The mucosal microbiome and IgA nephropathy: a new target for treatment?

IgA nephropathy (IgAN) poses a significant kidney failure risk, which can persist even when proteinuria is supressed to recommended targets [1]. This highlights an urgent need to initiate disease-modifying therapies early, beyond generic interventions designed for all proteinuric chronic kidney diseases (CKD). Development of these much-needed disease specific treatments requires detailed insights into the mechanisms which drive IgAN.